LAMP Pharma update! 44 Tage bis zur Expulsion? - 500 Beiträge pro Seite

[morchel]

March 19, 2002 07:01

LAM Pharmaceutical Corp. - LAM IPM(TM) Wound Gel Product Status Update on Pre-Marketing Notification 510(k) Filed With FDA
Jump to first matched term

LEWISTON, N.Y., March 19 /PRNewswire-FirstCall/ -- LAM Pharmaceutical, Corp. (OTC Bulletin Board: LAMP; Frankfurt: LAM), http://www.lampharm.com issued the following update concerning the current status of LAM IPM(TM) Wound Gel. On January 31, 2002 LAM Pharmaceutical, Corp. filed a 510(k) pre-market notification with the Food and Drug Administration in the United States for LAM IPM(TM) Wound Gel.

The FDA has assigned the following number to the 510(k) pre-market notification - K020325.

Formerly known as "LAM Ulcer Matrix," the product is now known as LAM IPM(TM) Wound Gel.

Under F.D.A. guidelines, the Company expects to receive a decision by April 30, 2002 regarding the status of LAM IPM(TM) Wound Gel`s suitability to be marketed.

Under supervision of a healthcare professional, LAM IPM(TM) Wound Gel is suitable for exuding wounds such as:

* Diabetic ulcers
* Leg ulcers
* Pressure ulcers
* Management of wounds that are prone to bleeding, such as wounds that
have been mechanically or surgically debrided.

LAM`s Chief Executive Officer, Alan Drizen, said, "We are excited and most proud that eight years of research and development have brought us to this important juncture where the results of our hard work are allowing us to commercialize our proprietary and patented technologies."

As promised, the company has delivered on completing the following important steps to help ensure the success of its first commercial product. These include:

* Richard Brokenshire joined LAM in the newly created position as
Vice President, Sales & Marketing.
* LAM signed an agreement to register IPM(TM) Wound Gel in Mexico.
* Exygen Research was appointed as quality control specialists and
will provide analytical and other technical services to assist in
the commercialization of LAM`s entire product portfolio.
* LAM signed a marketing agreement with RxCentric Inc. of New York
City.
* Packaging design for IPM(TM) Wound Gel has been completed.

In the Company`s opinion, revenue forecasts of US$ 27.0 million for 2003 and US$ 50.0 million for 2004 calendar year are both realistic and achievable, given the size (U.S. 2.5 billion plus) of the wound care market segment on which LAM IPM(TM) Wound Gel impacts.

"This 510(k) submission is a critical milestone for LAM Pharmaceutical, Corp.," Joseph Slechta, President & Chief Operating Officer commented. "With anticipated FDA clearance of LAM IPM(TM) Wound Gel, LAM has successfully initiated manufacturing, marketing and distribution channels which will position the Company to begin sales of the product in the early part of the third quarter 2002. Revenues should commence within this time frame. Successful introduction of this product within our stated timetable should lead to growing confidence in the investing community of LAM`s ability to execute its growth strategy. Other significant products are well past the planning stage and should incrementally add to our revenues and earnings in 2003 and beyond," Slechta concluded.

About LAM Pharmaceutical, Corp.

LAM Pharmaceutical, Corp. is a biomedical company with laboratories in Lewiston, New York, and a business office in Toronto. LAM focuses on the development and commercialization of novel wound healing and transdermal drug delivery systems that offer patients, among other benefits, safer and more effective treatment for a variety of serious diseases. The technology is based on an original Ionic Polymer Matrix(TM) technology (IPM(TM)), a proprietary and patented combination (a total of nine U.S. issued patents) of electrically charged and non-charged molecules with wound-healing properties. IPM(TM) technology combines with well-established drugs, allowing for the sustained delivery of greater amounts to the target areas than is otherwise possible and thus prolonging therapeutic activity.

The main ingredient of the Ionic Polymer Matrix(TM) technology is a derivative of hyaluronic acid, a molecule normally found in the skin and joints of bones. Hyaluronic acid is a non-immunogenic (the body does not react to it) and it is involved in such important biological functions as tissue hydration and proteoglycan organization (formation of proteins and sugars) to optimize tissue repair and prevent tissue aging. As well, hyaluronic acid is present in high concentration in fetal skin where wound healing is rapid and leaves little scarring.

LAM IPM(TM) Wound Gel is a clear, viscous, aqueous, odorless gel composed principally of sodium hyaluronate, a derivative salt of Hyaluronic acid. LAM IPM(TM) Wound Gel has demonstrated in both human and animal trials to be of significant value in the management of certain skin ulcers and wounds where maintaining a moist environment is supportive of the healing process. In human skin, Hyaluronic acid is involved in such important biological functions as tissue hydration and proteoglycan organization (formation of proteins and sugars).

As of December 31, 2001, LAM had nine issued patents in the United States. LAM IPM(TM) Wound Gel is protected by one or more of the following patents: 5,887,880; 6,120,804; 6,007,843; 6,063,405. All referenced patents have been issued to LAM Pharmaceutical, Corp. by the United States Patent Office and have subsequently been filed on a global basis.

The Company`s list of products under development include the following:

LAM IPM(TM) -- Extreme Dry Skin Formula -- A gel formula designed to saturate the stratum corneum, to relieve the symptoms of eczema, dermatitis and extremely dry skin.

LAM IPM(TM) -- Female Sexual Dysfunction Matrix -- a product that provides enhanced lubrication while also allowing the external structures of the female genitalia to be flushed with greater blood supply.

LAM IPM(TM) -- Motion Sickness Matrix -- a product currently under development, which is a topically applied delivery system, using a patch, of a well-known motion sickness drug.

LAM IPM(TM) -- Arthritic Pain Matrix -- is a clear aqueous gel that contains a well proven off patent drug.

For more information please visit our website at http://www.lampharm.com or send us an e-mail at [e-mail] to receive the latest information and press releases.


Wer sich für LAM Pharma und ihre Wundersalbe interessiert....es gibt viele informative Thredas hier an Board!

morchel

[morchel]

...sorry wegen der Überschrift....

[BlackAngel]

@ morchel

macht doch nichts, hauptsache das Ergebnis ist gut. Im übrigen, könntest du deine Aktienvorstellung zu Flexible Solutions noch einmal in einem neuen Thread wiederholen ? Damit man das dann über Aktiensuche auch findet.


Danke blacky